Teva Pharmaceutical Industries Limited (TEVA) exhibits 51.8% gross margins and 9.4% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 20.8x enterprise multiple and 4.8% implied options volatility.
Sustained 51.8% gross profitability converts into 12.5% operating margin and 9.4% ROIC, outpacing sector cost of capital.
ROIC: 9.4% // GM: 51.8%YoY revenue trajectory of +4.3% paired with 1.81% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +4.3% // FCF YLD: 1.81%Altman Z-Score of 1.02 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.02 // F-SCORE: 8/9Trading at 34.3x trailing P/E (31.9x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 34.3x // EV/EBITDA: 20.8xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $42.09 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.2% net margins.
NET MARGIN: 8.2% // D/E: 1.74x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TEVA & activate live FRED threshold breach alerts.